Bristol Myers Squibb Company (NYSE:BMY) Stake Lessened by Keybank National Association OH

Keybank National Association OH trimmed its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 1.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 559,598 shares of the biopharmaceutical company's stock after selling 9,299 shares during the quarter. Keybank National Association OH's holdings in Bristol Myers Squibb were worth $34,130,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. Pinney & Scofield Inc. acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter valued at approximately $25,000. Park Square Financial Group LLC bought a new stake in Bristol Myers Squibb during the fourth quarter valued at $26,000. Fairway Wealth LLC acquired a new stake in shares of Bristol Myers Squibb during the fourth quarter worth $28,000. Transce3nd LLC bought a new position in shares of Bristol Myers Squibb in the 4th quarter worth about $28,000. Finally, Global Wealth Strategies & Associates boosted its holdings in shares of Bristol Myers Squibb by 137.5% in the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 275 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on BMY. William Blair reiterated a "market perform" rating on shares of Bristol Myers Squibb in a research note on Friday, April 25th. Argus upgraded Bristol Myers Squibb to a "hold" rating in a research report on Friday, April 25th. UBS Group cut their price target on Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a report on Friday, April 11th. Wall Street Zen lowered Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. Finally, Cantor Fitzgerald reissued a "neutral" rating and set a $55.00 price target on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $58.00.

Insiders Place Their Bets

In other Bristol Myers Squibb news, EVP Samit Hirawat acquired 4,250 shares of Bristol Myers Squibb stock in a transaction dated Friday, April 25th. The stock was bought at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the transaction, the executive vice president owned 83,513 shares in the company, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.09% of the company's stock.

Bristol Myers Squibb Trading Up 0.3%

Bristol Myers Squibb stock opened at $47.64 on Thursday. Bristol Myers Squibb Company has a 12-month low of $39.35 and a 12-month high of $63.33. The stock has a market capitalization of $96.95 billion, a PE ratio of 17.84, a price-to-earnings-growth ratio of 1.41 and a beta of 0.36. The firm has a 50 day simple moving average of $47.78 and a 200-day simple moving average of $53.75. The company has a debt-to-equity ratio of 2.65, a current ratio of 1.28 and a quick ratio of 1.17.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The firm had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. During the same period last year, the company posted ($4.40) EPS. The firm's quarterly revenue was down 5.6% on a year-over-year basis. As a group, equities research analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd will be given a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.21%. The ex-dividend date is Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 92.88%.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.